CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,119 | -3.9% | 24,656 | +19.0% | 0.01% | 0.0% |
| Q2 2023 | $1,164 | +89.9% | 20,726 | +37.3% | 0.01% | +50.0% |
| Q4 2022 | $613 | -99.9% | 15,090 | +12.9% | 0.00% | -42.9% |
| Q3 2022 | $873,000 | +20.9% | 13,361 | +12.5% | 0.01% | +40.0% |
| Q2 2022 | $722,000 | +76.1% | 11,877 | +81.9% | 0.01% | +66.7% |
| Q1 2022 | $410,000 | +22.8% | 6,531 | +48.0% | 0.00% | +50.0% |
| Q4 2021 | $334,000 | -45.3% | 4,414 | -19.2% | 0.00% | -60.0% |
| Q3 2021 | $611,000 | -27.3% | 5,460 | +5.2% | 0.01% | -28.6% |
| Q2 2021 | $840,000 | +71.8% | 5,191 | +29.3% | 0.01% | +40.0% |
| Q1 2021 | $489,000 | -23.7% | 4,016 | -4.1% | 0.01% | -28.6% |
| Q4 2020 | $641,000 | – | 4,188 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |